CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|August 1, 2003
Reyataz (Atazanavir)
Protease inhibitor for once-daily administration
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
When the referral isn't the finish line: Making SDOH programs actually close care gaps
2
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
3
New lean MASH mouse model could guide more targeted liver disease treatment in humans
4
CMS defined a path for medical frailty. Now comes the hard part.
5